Mediwelcome Healthcare Management & Technology Inc. 2025 Annual Report: Key Insights for Investors

Strong Turnaround and Significant Corporate Developments in 2025

Mediwelcome Healthcare Management & Technology Inc. has reached a pivotal moment in its operations and financial performance, as reflected in its 2025 Annual Report. The Group, which provides medical conference services, patient education and screening, marketing strategy and consulting, as well as CRO and internet hospital services, has transitioned from an investment-heavy phase to self-sustaining, profitable growth. The commercial application of medical AI has started to deliver results, and the company is now operating from a position of historic financial strength.

Key Financial Highlights

• Revenue Growth: The Group reported revenue of RMB 468.0 million for 2025, a substantial increase from RMB 321.6 million in 2024.
• Profitability: Net profit for 2025 was RMB 7.0 million, compared to a net loss of RMB 46.9 million in 2024. Profit attributable to owners was RMB 10.0 million.
• Turnaround in Gross Profit: Gross profit increased to RMB 94.7 million (2024: RMB 51.0 million), reflecting both revenue growth and improved operational efficiency.
• Operating Expenses: Selling expenses increased by 24.6% to RMB 25.8 million, mainly due to expanded customer networks and business promotion. R&D expenditure rose to RMB 27.9 million (2024: RMB 18.7 million), highlighting continued investment in technology.
• Impairment and Fair Value Movements: The company reversed previous impairment losses on intangible assets, recording a gain of RMB 9.3 million. However, other income turned negative (a net loss of RMB 1.0 million) due to lower government subsidies and higher foreign exchange losses.
• Earnings Per Share (EPS): Basic and diluted EPS was RMB 4.38 cents, compared to a loss per share of RMB 23.63 cents in 2024.
• No Dividend Declared: The Board has resolved not to recommend any final dividend for 2025.

Capital Market Activities and Shareholder Structure

• Successful Share Placings: The Company completed two placings of 40 million new shares each in June and July 2025, raising aggregate net proceeds of approximately HK\$36.9 million. The capital markets showed strong confidence in the Group’s business model and prospects.
• Share Capital Increase: Following the placings, the number of issued shares increased from 200 million to 280 million, with no treasury shares held by the Company as of 31 December 2025.
• Shareholding Structure: The controlling shareholders, including Mr. Shi Wei, Mr. Yang Weimin, Ms. Zhang Yitao, and Mr. Wang Liang, collectively hold more than 38% of the Company’s shares via various investment vehicles, acting in concert.

Strategic Transactions and Investments

• Equity Investments: The Group’s equity investments at fair value through other comprehensive income (FVTOCI) fell due to fair value losses, particularly in Shanghai Bohuikang. No dividend was received from these investments during the year.
• Discloseable Transaction: On 13 June 2025, a key subsidiary completed a capital reduction and disposed of its entire interest in Beijing Haice for RMB 7.0 million. Beijing Haice is no longer consolidated into the Group’s financials.
• Potential Acquisition (Post-Year-End Event): In January 2026, a subsidiary entered into a non-binding MOU for the possible acquisition of 100% of MediAI Technology Development Limited, which develops AI for pharmaceutical research and uses blockchain for data traceability. This deal, if completed, could significantly enhance the Group’s technology portfolio and competitiveness.

Operational and Business Risks

• Regulatory Structure: Due to PRC restrictions on foreign investments in certain healthcare and internet services, the Group operates some businesses via Contractual Arrangements (VIE structure). The Company has taken steps to comply with evolving PRC laws, but there are risks related to regulatory interpretation, enforcement, and future changes that could materially affect operations.
• Concentration Risks: In 2025, the largest customer contributed 28% of revenues, and the top five customers accounted for 57%. On the supplier side, the largest accounted for 46% of purchases, with the top five at 55%. Such concentration exposes the Company to risks if relationships with key partners are disrupted.
• Fair Value Risks: The Group remains exposed to fair value fluctuations in its unlisted equity investments. Internal controls and annual reviews are in place to monitor performance and manage risks.

Corporate Governance and Audit

• Corporate Governance: The Company has a robust governance framework, with full compliance to the Hong Kong Listing Rules and the Corporate Governance Code throughout 2025. The Board, Audit, Remuneration, and Nomination Committees are all active, and risk management and internal controls are regularly reviewed and externally assessed.
• Auditor Change: Moore CPA Limited resigned as the Company’s auditor on 28 November 2025. Rongcheng (Hong Kong) CPA Limited was appointed as the new auditor and has issued an unqualified opinion on the 2025 financial statements.

Other Important Shareholder Information

• No Final Dividend: Consistent with the Company’s dividend policy and considering its operational requirements, no final dividend was proposed for 2025. There were no arrangements for the waiver of dividends by shareholders.
• Shareholder Rights: Shareholders holding at least 10% of paid-up capital have the right to convene extraordinary general meetings. The Company has detailed procedures for shareholder proposals and enquiries, with dedicated contact points for both governance and shareholding matters.
• Share Option and RSU Schemes: The Company maintains both restricted share unit (RSU) and share option schemes to incentivize management and employees. Details of these schemes, including eligibility, vesting, and limits, are fully disclosed in the annual report.

Potential Price-Sensitive Matters

• Return to Profitability: The swing from a significant loss in 2024 to profit in 2025 marks a material inflection point and may positively impact investor sentiment and share price expectations.
• Share Placements and Capital Raise: The successful capital raise via two large share placings in mid-2025 strengthens the balance sheet and supports future growth, but also dilutes existing shareholders.
• Potential Acquisition of MediAI Technology Development Limited: This post-year-end potential deal, if completed, could have a major impact on Mediwelcome’s technology capabilities and is highly price-sensitive due to its strategic nature in AI and blockchain for healthcare.
• Regulatory Risks in VIE Structure: Changes in PRC law or enforcement regarding foreign investment in healthcare and internet services could have a material adverse effect on the Company’s operations and valuation.
• Customer and Supplier Concentration: High dependence on a few customers and suppliers makes the Company vulnerable to business disruptions or contract losses, which could affect earnings and share price volatility.
• Change of Auditor: While the new auditor issued an unqualified opinion, any auditor change can be perceived as a risk factor by some investors.

Conclusion

Mediwelcome Healthcare Management & Technology Inc. has demonstrated a strong financial turnaround in 2025 with robust revenue growth, a return to profitability, and strengthened capital resources. However, investors should remain vigilant about regulatory risks, customer/supplier concentration, and the outcome of the potential MediAI acquisition. These factors, combined with no dividend payout and a change in auditor, are all price-sensitive and should be closely monitored for their potential impact on shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult with professional advisers before making any investment decisions. All financial data and forward-looking statements are as reported by Mediwelcome Healthcare Management & Technology Inc. in its 2025 Annual Report. No liability is accepted for any losses arising from reliance on this summary.

View MEDIWELCOME Historical chart here